CHINAUS AFRICAASIA 中文双语Français
Business\Economy

China fines domestic medicine companies for monopoly pricing

Xinhua | Updated: 2017-07-31 16:29
BEIJING - China's top economic planner announced Monday that two domestic medicine firms had been fined for monopoly pricing practices.

Zhejiang Second Pharma and Tianjin Handewei Pharmaceutical were fined a total of 443,900 yuan ($65,975) for fixing prices for an active pharmaceutical ingredient, said a National Development and Reform Commission (NDRC) statement.

The two companies charged an unfairly high price for Isoniazid, an antibiotic used to treat tuberculosis, and declined sales with no justified cause, the statement said.

The two companies have since restored regular pricing and revived market competition.

Monopoly practices in the pharmaceutical sector have been a focus of China's anti-monopoly supervision for some time. The case will help regulate active pharmaceutical ingredient pricing and ensure a fair environment for medicine purchases and sales, according to the NDRC.

The NDRC has vowed to increase anti-monopoly supervision to protect market order, consumers and businesses.
BACK TO THE TOP
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US